Le CagriSema 2,4 mg/2,4 mg de Novo Nordisk a démontré des effets significatifs sur la réduction du taux d’HbA1c et du poids corporel dans de multiples études du programme REIMAGINE.
Plainsboro, NJ et Baggesworth, Danemark, le 7 juin 2026 /PRNewswire/ -- Novo Nordisk a annoncé aujourd'hui les résultats de la phase 3 de son essai REIMAGINE 1-3, montrant des rédu…
该文章暂未提取到完整正文，已从资讯列表和商品关联资讯中自动隐藏。你可以返回文章列表继续浏览其他内容。
Questions frequentes
Which products are related to this article?
No strongly related product has been identified yet. The match updates automatically when the article or catalog changes.
How can I view the medicines discussed in this article?
Use the related product cards below the article to review available specifications, prices, product information, and reviews.
Does this article replace advice from a doctor or pharmacist?
No. This content is for general information and health education only. Follow the prescription and individual guidance provided by qualified healthcare professionals.
